Have we pushed the needle for treatment of Type 1 diabetes?

Current Opinion in Immunology

Volumn 49, Issue , 2017, Pages 44-50

  Naushad, Nida ^a   Perdigoto, Ana Luisa ^a   Rui, Jinxiu ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALUMINUM POTASSIUM SULFATE; ANAKINRA; C PEPTIDE; CANAKINUMAB; ETANERCEPT; GLUTAMATE DECARBOXYLASE 65; IMATINIB; INSULIN; INTERLEUKIN 2; OMEPRAZOLE; OTELIXIZUMAB; RAPAMYCIN; RITUXIMAB; SITAGLIPTIN; TEPLIZUMAB; AUTOANTIGEN; BIOLOGICAL PRODUCT;

ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEDIFFERENTIATION; CELL PROTECTION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MEDICAL CARE; PANCREAS ISLET BETA CELL; PATHOGENESIS; REVIEW; ANIMAL; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; AUTOANTIGENS; BIOLOGICAL PRODUCTS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; MOLECULAR TARGETED THERAPY;

EID: 85030686108     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2017.09.004     Document Type: Review

References (64)

1. Vehik, K., Beam, C.A., Mahon, J.L., Schatz, D.A., Haller, M.J., Sosenko, J.M., Skyler, J.S., Krischer, J.P., Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 34 (2011), 1897–1901.
2. Orban, T., Sosenko, J.M., Cuthbertson, D., Krischer, J.P., Skyler, J.S., Jackson, R., Yu, L., Palmer, J.P., Schatz, D., Eisenbarth, G., Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32 (2009), 2269–2274.
3. Ferrannini, E., Mari, A., Nofrate, V., Sosenko, J.M., Skyler, J.S., Group, D.P.T.S., Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 59 (2010), 679–685.
4. Herold, K.C., Usmani-Brown, S., Ghazi, T., Lebastchi, J., Beam, C.A., Bellin, M.D., Ledizet, M., Sosenko, J.M., Krischer, J.P., Palmer, J.P., beta Cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 125 (2015), 1163–1173.
5. Greenbaum, C.J., Beam, C.A., Boulware, D., Gitelman, S.E., Gottlieb, P.A., Herold, K.C., Lachin, J.M., McGee, P., Palmer, J.P., Pescovitz, M.D., et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite TrialNet Data. Diabetes, 2012.
6. Ziegler, A.G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309 (2013), 2473–2479.
7. Yu, L., Robles, D.T., Abiru, N., Kaur, P., Rewers, M., Kelemen, K., Eisenbarth, G.S., Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 97 (2000), 1701–1706.
8. Torrente-Segarra, V., Salman Monte, T.C., Rua-Figueroa, I., Sanchez-Alonso, F., Lopez-Longo, F.J., Galindo-Izquierdo, M., Calvo-Alen, J., Olive-Marques, A., Ibanez-Ruan, J., Horcada, L., et al. Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Clin Exp Rheumatol, 2017.
9. Bougneres, P.F., Carel, J.C., Castano, L., Boitard, C., Gardin, J.P., Landais, P., Hors, J., Mihatsch, M.J., Paillard, M., Chaussain, J.L., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318 (1988), 663–670.
10. Stiller, C.R., Dupre, J., Gent, M., Jenner, M.R., Keown, P.A., Laupacis, A., Martell, R., Rodger, N.W., von Graffenried, B., Wolfe, B.M., Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223 (1984), 1362–1367.
11. Hagopian, W., Ferry, R.J. Jr., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K.E., Koenig, S., Daifotis, A.G., Herold, K.C., et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 62 (2013), 3901–3908.
12. Herold, K.C., Gitelman, S.E., Ehlers, M.R., Gottlieb, P.A., Greenbaum, C.J., Hagopian, W., Boyle, K.D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes, 2013.
13. Herold, K.C., Gitelman, S.E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D.M., Bluestone, J.A., A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005), 1763–1769.
14. Herold, K.C., Hagopian, W., Auger, J.A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S.E., Harlan, D.M., Xu, D., Zivin, R.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 (2002), 1692–1698.
15. Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S.M., Wahlen, J., Ferry, R.J. Jr., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet, 2011.
16. Keymeulen, B., Vandemeulebroucke, E., Ziegler, A.G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005), 2598–2608.
17. Glycemic Targets. Diabetes Care 40 (2017), S48–S56.
18. Tooley, J.E., Vudattu, N., Choi, J., Cotsapas, C., Devine, L., Raddassi, K., Ehlers, M.R., McNamara, J.G., Harris, K.M., Kanaparthi, S., et al. Changes in T-cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes. Eur J Immunol, 2015.
19. Long, S.A., Thorpe, J., DeBerg, H.A., Gersuk, V., Eddy, J., Harris, K.M., Ehlers, M., Herold, K.C., Nepom, G.T., Linsley, P.S., Partial exhaustion of CD8T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol, 1, 2016 The authors identified a population of CD8+ T cells in patients with the best response to the anti-CD3 monoclonal antibody teplizumab. These cells resembled exhausted T cells, suggesting that induction of exhaustion may be a therapeutic strategy for T1D.
20. McKinney, E.F., Lee, J.C., Jayne, D.R., Lyons, P.A., Smith, K.G., T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523 (2015), 612–616 The authors found that CD8+ T cell exhaustion predicts better prognosis in autoimmune disease, suggesting a new therapeutic approach for autoimmune diseases.
21. McKinney, E.F., Lyons, P.A., Carr, E.J., Hollis, J.L., Jayne, D.R., Willcocks, L.C., Koukoulaki, M., Brazma, A., Jovanovic, V., Kemeny, D.M., et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 16 (2010), 586–591 [581p following 591p].
22. Rigby, M., DiMeglio, L., Rendell, M., Felner, E., Dostou, J., Gitelman, S., Patel, C., Griffin, K., Tsalikian, E., Gottlieb, P., et al. Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the TIDAL study. Lancet Endocrinol Metab, 2013.
23. Rigby, M.R., Harris, K.M., Pinckney, A., DiMeglio, L.A., Rendell, M.S., Felner, E.I., Dostou, J.M., Gitelman, S.E., Griffin, K.J., Tsalikian, E., et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125 (2015), 3285–3296.
24. Pescovitz, M.D., Greenbaum, C.J., Bundy, B., Becker, D.J., Gitelman, S.E., Goland, R., Gottlieb, P.A., Marks, J.B., Moran, A., Raskin, P., et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37 (2014), 453–459.
25. Pescovitz, M.D., Greenbaum, C.J., Krause-Steinrauf, H., Becker, D.J., Gitelman, S.E., Goland, R., Gottlieb, P.A., Marks, J.B., McGee, P.F., Moran, A.M., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361 (2009), 2143–2152.
26. Herold, K.C., Pescovitz, M.D., McGee, P., Krause-Steinrauf, H., Spain, L.M., Bourcier, K., Asare, A., Liu, Z., Lachin, J.M., Dosch, H.M., Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (Rituximab) therapy in type 1 diabetes. J Immunol 187 (2011), 1998–2005.
27. Chamberlain, N., Massad, C., Oe, T., Cantaert, T., Herold, K.C., Meffre, E., Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest 126 (2016), 282–287.
28. Gitelman, S.E., Gottlieb, P.A., Rigby, M.R., Felner, E.I., Willi, S.M., Fisher, L.K., Moran, A., Gottschalk, M., Moore, W.V., Pinckney, A., et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 1 (2013), 306–316.
29. Haller, M.J., Gitelman, S.E., Gottlieb, P.A., Michels, A.W., Rosenthal, S.M., Shuster, J.J., Zou, B., Brusko, T.M., Hulme, M.A., Wasserfall, C.H., et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest 125 (2015), 448–455.
30. McClymont, S.A., Putnam, A.L., Lee, M.R., Esensten, J.H., Liu, W., Hulme, M.A., Hoffmuller, U., Baron, U., Olek, S., Bluestone, J.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186 (2011), 3918–3926.
31. Hundhausen, C., Roth, A., Whalen, E., Chen, J., Schneider, A., Long, S.A., Wei, S., Rawlings, R., Kinsman, M., Evanko, S.P., et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med, 8, 2016, 356ra119.
32. Koreth, J., Matsuoka, K., Kim, H.T., McDonough, S.M., Bindra, B., Alyea, E.P. 3rd, Armand, P., Cutler, C., Ho, V.T., Treister, N.S., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365 (2011), 2055–2066.
33. Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., Klatzmann, D., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365 (2011), 2067–2077.
34. Long, S.A., Rieck, M., Sanda, S., Bollyky, J.B., Samuels, P.L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61 (2012), 2340–2348.
35. Marek-Trzonkowska, N., Mysliwiec, M., Dobyszuk, A., Grabowska, M., Techmanska, I., Juscinska, J., Wujtewicz, M.A., Witkowski, P., Mlynarski, W., Balcerska, A., et al. Administration of CD4+ CD25highCD127− regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 35 (2012), 1817–1820 This report and the following Ref. [36] describe early experiences with the use of polyclonal regulatory T cells as treatment for T1D.
36. Bluestone, J.A., Buckner, J.H., Fitch, M., Gitelman, S.E., Gupta, S., Hellerstein, M.K., Herold, K.C., Lares, A., Lee, M.R., Li, K., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med, 7, 2015, 315ra189 See annotation to Ref. [35].
37. Skyler, J.S., Krischer, J.P., Wolfsdorf, J., Cowie, C., Palmer, J.P., Greenbaum, C., Cuthbertson, D., Rafkin-Mervis, L.E., Chase, H.P., Leschek, E., Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial — Type 1. Diabetes Care 28 (2005), 1068–1076.
38. Bonifacio, E., Ziegler, A.G., Klingensmith, G., Schober, E., Bingley, P.J., Rottenkolber, M., Theil, A., Eugster, A., Puff, R., Peplow, C., et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 313 (2015), 1541–1549.
39. Wherrett, D.K., Bundy, B., Becker, D.J., Dimeglio, L.A., Gitelman, S.E., Goland, R., Gottlieb, P.A., Greenbaum, C.J., Herold, K.C., Marks, J.B., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet, 2011.
40. Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castano, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366 (2012), 433–442.
41. Alhadj Ali, M., Liu, Y.F., Arif, S., Tatovic, D., Shariff, H., Gibson, V.B., Yusuf, N., Baptista, R., Eichmann, M., Petrov, N., et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med, 2017, 9.
42. Roep, B.O., Solvason, N., Gottlieb, P.A., Abreu, J.R.F., Harrison, L.C., Eisenbarth, G.S., Yu, L., Leviten, M., Hagopian, W.A., Buse, J.B., et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes. Sci Transl Med, 5, 2013, 191ra182.
43. Delong, T., Wiles, T.A., Baker, R.L., Bradley, B., Barbour, G., Reisdorph, R., Armstrong, M., Powell, R.L., Reisdorph, N., Kumar, N., et al. Pathogenic CD4T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351 (2016), 711–714.
44. Mohan, J.F., Levisetti, M.G., Calderon, B., Herzog, J.W., Petzold, S.J., Unanue, E.R., Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 11 (2010), 350–354.
45. Mohan, J.F., Petzold, S.J., Unanue, E.R., Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208 (2011), 2375–2383.
46. Morita, S., Villalta, S.A., Feldman, H.C., Register, A.C., Rosenthal, W., Hoffmann-Petersen, I.T., Mehdizadeh, M., Ghosh, R., Wang, L., Colon-Negron, K., et al. Targeting ABL-IRE1alpha signaling spares ER-stressed pancreatic beta cells to reverse autoimmune diabetes. Cell Metab 25 (2017), 883–897.e888 The authors show that ER stress contributes to β cell death, and they identify the ABL-IRE1α axis as a potential drug target to treat T1D.
47. Talchai, C., Xuan, S., Lin, H.V., Sussel, L., Accili, D., Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150 (2012), 1223–1234.
48. Rui, J., Deng, S., Arazi, A., Perdigoto, A.L., Liu, Z., Herold, K.C., beta Cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. Cell Metab, 2017 The authors identified a population of β cells in NOD mice that are resistant to immune attack. These cells express fewer β cell identify genes and express more immune inhibitory markers. Identifying drugs that can indcue similar changes in β cells could present novel therapies for T1D.
49. Keenan, H.A., Sun, J.K., Levine, J., Doria, A., Aiello, L.P., Eisenbarth, G., Bonner-Weir, S., King, G.L., Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59 (2010), 2846–2853.
50. Couri, C.E., Oliveira, M.C., Stracieri, A.B., Moraes, D.A., Pieroni, F., Barros, G.M., Madeira, M.I., Malmegrim, K.C., Foss-Freitas, M.C., Simoes, B.P., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301 (2009), 1573–1579.
51. Chaillous, L., Lefevre, H., Thivolet, C., Boitard, C., Lahlou, N., Atlan-Gepner, C., Bouhanick, B., Mogenet, A., Nicolino, M., Carel, J.C., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356 (2000), 545–549.
52. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346 (2002), 1685–1691.
53. Nanto-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipila, J.I., Haavisto, L., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372 (2008), 1746–1755.
54. Fourlanos, S., Perry, C., Gellert, S.A., Martinuzzi, E., Mallone, R., Butler, J., Colman, P.G., Harrison, L.C., Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60 (2011), 1237–1245.
55. Ludvigsson, J., Faresjo, M., Hjorth, M., Axelsson, S., Cheramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359 (2008), 1909–1920.
56. Herold, K.C., Gitelman, S.E., Ehlers, M.R., Gottlieb, P.A., Greenbaum, C.J., Hagopian, W., Boyle, K.D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62 (2013), 3766–3774.
57. Herold, K.C., Gitelman, S.E., Willi, S.M., Gottlieb, P.A., Waldron-Lynch, F., Devine, L., Sherr, J., Rosenthal, S.M., Adi, S., Jalaludin, M.Y., et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56 (2013), 391–400.
58. Aronson, R., Gottlieb, P.A., Christiansen, J.S., Donner, T.W., Bosi, E., Bode, B.W., Pozzilli, P., Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37 (2014), 2746–2754.
59. Orban, T., Bundy, B., Becker, D.J., Dimeglio, L.A., Gitelman, S.E., Goland, R., Gottlieb, P.A., Greenbaum, C.J., Marks, J.B., Monzavi, R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet, 2011.
60. Moran, A., Bundy, B., Becker, D.J., DiMeglio, L.A., Gitelman, S.E., Goland, R., Greenbaum, C.J., Herold, K.C., Marks, J.B., Raskin, P., et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381 (2013), 1905–1915.
61. Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., Quattrin, T., Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32 (2009), 1244–1249.
62. Marek-Trzonkowska, N., Myśliwiec, M., Dobyszuk, A., Grabowska, M., Derkowska, I., Juścińska, J., Owczuk, R., Szadkowska, A., Witkowski, P., Młynarski, W., et al. Therapy of type 1 diabetes with CD4+ CD25highCD127-regulatory T cells prolongs survival of pancreatic islets — results of one year follow-up. Clin Immunol 153 (2014), 23–30.
63. Gitelman, S.E., Bluestone, J.A., Regulatory T cell therapy for type 1 diabetes: may the force be with you. J Autoimmun 71 (2016), 78–87.
64. Griffin, K.J., Thompson, P.A., Gottschalk, M., Kyllo, J.H., Rabinovitch, A., Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2 (2014), 710–718.